HRS-5635 Injection

DRUG2 trials

Sponsors

Fujian Shengdi Pharmaceutical Co., Ltd.

Conditions

Chronic Hepatitis BNucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B

Phase 2

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

RecruitingNCT06425341

Fujian Shengdi Pharmaceutical Co., Ltd.Chronic Hepatitis B

Start: 2024-06-06End: 2027-01-19Target: 369Updated: 2025-11-17

Phase 3

Phase III Study of HRS-5635 in Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B

RecruitingNCT07606950

Fujian Shengdi Pharmaceutical Co., Ltd.Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B

Start: 2026-07-17End: 2028-06-01Target: 540Updated: 2026-07-24